Thrombosis was rare (0.5%) and primarily linked to baseline conditions; however, the retrospective design and limited number of events (n = 33) prevent definitively excluding a contribution from SGLT-2 inhibitor-associated erythrocytosis. The gene discussed is SLC5A2; the disease is Venous thrombosis.